Inclusion Criteria:

          -  Core-binding factor (CBF) AML with molecular diagnosis of RUNX1-RUNX1T1 fusion
             transcript resulting from t(8;21)(q22;q22.1) (or a variant form) or of CBFB-MYH11
             fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in
             one of the central AMLSG reference laboratories (Ulm, Hannover)

          -  Age ≥ 18; there is no upper age limit

          -  No prior chemotherapy for leukemia except hydroxyurea for up to 5 days during the
             diagnostic screening phase

          -  Non-pregnant and non-nursing. Due to the unknown teratogenic potential of dasatinib in
             humans, pregnant or nursing patients may not be enrolled. Women of childbearing
             potential (WOCBP) must have a negative serum or urine pregnancy test within a
             sensitivity of at least 25 mIU/mL with-in 72 hours prior to registration. Women of
             child-bearing potential must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control - one highly effective
             method (e.g., IUD, hormonal, tubal ligation, or partner's vasectomy), and one
             additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE
             SAME TIME, at least four weeks before she begins dasatinib therapy. "Women of
             childbearing potential" is defined as a sexually active mature woman who has not
             undergone a hysterectomy or who has had menses at any time in the preceding 24
             consecutive months.

          -  Men must agree not to father a child and must use a latex condom during any sexual
             contact with women of childbearing potential while taking dasatinib and for 3 months
             after therapy is stopped, even if they have undergone a successful vasectomy.

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Performance status WHO >2

          -  Pulmonary edema and/or pleural/pericardial effusion within 14 days of day 1. If
             edema/effusion resolves to CTC Grade ≤1, patients can be treated with dasatinib.

          -  Patients with ejection fraction <50% by echocardiography within 14 days of day 1

          -  Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or AP
             >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or
             restrictive ventilation disorder)

          -  Uncontrolled infection

          -  Patients with a "currently active" second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a "currently active" malignancy, if they
             have completed therapy and are considered by their physician to be at less than 30%
             risk of relapse within one year.

          -  Severe neurological or psychiatric disorder interfering with ability of giving an
             informed consent

          -  Known positive for HIV, active HBV, HCV, or Hepatitis A infection

          -  Bleeding disorder independent of leukemia

          -  No consent for registration, storage and processing of the individual disease
             characteristics and course as well as information of the family physician and/or other
             physicians involved in the treatment of the patient about study participation.

          -  No consent for biobanking.